Close Menu
    Facebook LinkedIn YouTube WhatsApp X (Twitter) Pinterest
    Trending
    • AI evolves itself to speed up scientific discovery
    • Australia’s privacy commissioner tried, in vain, to sound the alarm on data protection during the u16s social media ban trials
    • Nothing Phone (4a) Pro Review: A Close Second
    • Match Group CEO Spencer Rascoff says growing women’s share on Tinder is his “primary focus” to stem user declines; Sensor Tower says 75% of Tinder users are men (Kieran Smith/Financial Times)
    • Today’s NYT Connections Hints, Answers for April 20 #1044
    • AI Machine-Vision Earns Man Overboard Certification
    • Battery recycling startup Renewable Metals charges up on $12 million Series A
    • The Influencers Normalizing Not Having Sex
    Facebook LinkedIn WhatsApp
    Times FeaturedTimes Featured
    Monday, April 20
    • Home
    • Founders
    • Startups
    • Technology
    • Profiles
    • Entrepreneurs
    • Leaders
    • Students
    • VC Funds
    • More
      • AI
      • Robotics
      • Industries
      • Global
    Times FeaturedTimes Featured
    Home»Technology»Crispr Offers New Hope for Treating Diabetes
    Technology

    Crispr Offers New Hope for Treating Diabetes

    Editor Times FeaturedBy Editor Times FeaturedSeptember 11, 2025No Comments4 Mins Read
    Facebook Twitter Pinterest Telegram LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Telegram Email WhatsApp Copy Link


    Crispr gene-editing expertise has demonstrated its revolutionary potential in recent times: It has been used to treat rare diseases, to adapt crops to face up to the extremes of local weather change, and even to change the color of a spider’s net. However the biggest hope is that this technology will assist discover a treatment for a worldwide illness, similar to diabetes. A brand new research factors in that course.

    For the primary time, researchers succeeded in implanting Crispr-edited pancreatic cells in a person with kind 1 diabetes, an autoimmune illness the place the immune system assaults insulin-producing cells within the pancreas. With out insulin, the physique is then unable to control blood sugar. If steps aren’t taken to handle glucose ranges by different means (sometimes, by injecting insulin), this will result in injury to the nerves and organs—notably the center, kidneys, and eyes. Roughly 9.5 million folks worldwide have kind 1 diabetes.

    On this experiment, edited cells produced insulin for months after being implanted, with out the necessity for the recipient to take any immunosuppressive medicine to cease their physique attacking the cells. The Crispr expertise allowed the researchers to endow the genetically modified cells with camouflage to evade detection.

    The research, revealed final month in The New England Journal of Medicine, particulars the step-by-step process. First, pancreatic islet cells have been taken from a deceased donor with out diabetes, after which altered with the gene-editing approach Crispr-Cas12b to permit them to evade the immune response of the diabetes affected person. Cells altered like this are stated to be “hypoimmune,” explains Sonja Schrepfer, a professor at Cedars-Sinai Medical Heart in California and the scientific cofounder of Sana Biotechnology, the corporate that developed this remedy.

    The edited cells have been then implanted into the forearm muscle of the affected person, and after 12 weeks, no indicators of rejection have been detected. (A subsequent report from Sana Biotechnology notes that the implanted cells have been nonetheless evading the affected person’s immune system after six months.)

    Checks run as a part of the research recorded that the cells have been useful: The implanted cells secreted insulin in response to glucose ranges, representing a key step towards controlling diabetes with out the necessity for insulin injections. 4 hostile occasions have been recorded throughout follow-ups with the affected person, however none of them have been severe or straight linked to the modified cells.

    The researchers’ final purpose is to use immune-camouflaging gene edits to stem cells—which have the power to breed and differentiate themselves into different cell sorts contained in the physique—after which to direct their improvement into insulin-secreting islet cells. “The benefit of engineering hypoimmune stem cells is that when these stem cells proliferate and create new cells, the brand new cells are additionally hypoimmune,” Schrepfer defined in a Cedars-Sinai Q+A earlier this 12 months.

    Historically, transplanting international cells right into a affected person has required suppressing the affected person’s immune system to keep away from them being rejected. This carries important dangers: infections, toxicity, and long-term problems. “Seeing sufferers die from rejection or extreme problems from immunosuppression was irritating to me, and I made a decision to focus my profession on creating methods to beat immune rejection with out immunosuppressive medicine,” Schrepfer advised Cedars-Sinai.

    Though the analysis marks a milestone within the seek for therapies of kind 1 diabetes, it’s vital to notice that the research concerned one one participant, who obtained a low dose of cells for a brief interval—not sufficient for the affected person to not want to manage their blood sugar with injected insulin. An editorial by the journal Nature additionally says that some unbiased analysis teams have failed of their efforts to substantiate that Sana’s methodology supplies edited cells with the power to evade the immune system.

    Sana will probably be trying to conduct extra scientific trials beginning subsequent 12 months. With out overlooking the criticisms and limitations of the present research, the opportunity of transplanting cells modified to be invisible to the immune system opens up a really promising horizon in regenerative medication.

    This story initially appeared on WIRED en Español and has been translated from Spanish.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Editor Times Featured
    • Website

    Related Posts

    Nothing Phone (4a) Pro Review: A Close Second

    April 20, 2026

    The Influencers Normalizing Not Having Sex

    April 20, 2026

    Our Favorite Apple Watch Has Never Been Less Expensive

    April 19, 2026

    The 11 Best Fans to Buy Before It Gets Hot Again (2026)

    April 19, 2026

    Hisense U7SG TV Review (2026): Better Design, Great Value

    April 19, 2026

    Best Meta Glasses (2026): Ray-Ban, Oakley, AR

    April 19, 2026

    Comments are closed.

    Editors Picks

    AI evolves itself to speed up scientific discovery

    April 20, 2026

    Australia’s privacy commissioner tried, in vain, to sound the alarm on data protection during the u16s social media ban trials

    April 20, 2026

    Nothing Phone (4a) Pro Review: A Close Second

    April 20, 2026

    Match Group CEO Spencer Rascoff says growing women’s share on Tinder is his “primary focus” to stem user declines; Sensor Tower says 75% of Tinder users are men (Kieran Smith/Financial Times)

    April 20, 2026
    Categories
    • Founders
    • Startups
    • Technology
    • Profiles
    • Entrepreneurs
    • Leaders
    • Students
    • VC Funds
    About Us
    About Us

    Welcome to Times Featured, an AI-driven entrepreneurship growth engine that is transforming the future of work, bridging the digital divide and encouraging younger community inclusion in the 4th Industrial Revolution, and nurturing new market leaders.

    Empowering the growth of profiles, leaders, entrepreneurs businesses, and startups on international landscape.

    Asia-Middle East-Europe-North America-Australia-Africa

    Facebook LinkedIn WhatsApp
    Featured Picks

    AI Toys for Kids Talk About Sex, Drugs, and Chinese Propaganda

    December 13, 2025

    Bundesliga Soccer Livestream: How to Watch Bayern Munich vs. Mainz

    December 14, 2025

    OpenAI targets ~$60 per 1,000 views for ChatGPT ads, on par with live NFL broadcasts and above Meta’s sub-$20 CPM, while offering little conversion data (The Information)

    January 26, 2026
    Categories
    • Founders
    • Startups
    • Technology
    • Profiles
    • Entrepreneurs
    • Leaders
    • Students
    • VC Funds
    Copyright © 2024 Timesfeatured.com IP Limited. All Rights.
    • Privacy Policy
    • Disclaimer
    • Terms and Conditions
    • About us
    • Contact us

    Type above and press Enter to search. Press Esc to cancel.